Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19.
Biophytis Wins Major Legal Victory Before the French Court of Cassation Biophytis announces a major legal victory. On July 9, 2025, the French Court of Cassation, the country’s highest judicial authority, issued a landmark ruling partially overturning the decision of the Paris Court of Appeal and ruling in favor of…
Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artificial intelligence solutions for life sciences. The collaboration aims to…
Biophytis Reports 2024 Financial Results and 2025 Outlook Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible. Continued partnership strategy to support the funding of clinical programs. Strengthening of the drug discovery platform through the integration of disruptive technologies. Biophytis announced…
Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025 Biophytis announces its participation in the 7th edition of the World Aging & Rejuvenation Conference (ARC 2025), to be held in Vienna, Austria, from July 9 to 10, 2025. As part of this internationally renowned…
Obesity: Biophytis Charts Its Course Toward a Booming Market Biophytis is seizing a major opportunity in the expanding obesity market by addressing an unmet medical need: preserving muscle mass and function in patients losing weight while treated with GLP-1 receptor agonists. GLP-1 therapies such as semaglutide and tirzepatide have revolutionized…
Biophytis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025 Biophytis is proud to announce its successful participation at the BIO International Convention 2025, the world’s largest and most comprehensive biotechnology event. Hosted at the Boston Convention & Exhibition Center from June 16-19, 2025, the convention gathered…
Information on the Annual Financial Statements Biophytis announces that it is not in a position to publish its 2024 annual accounts on the previously scheduled date. Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest. Fullscreen Mode
Biophytis announces the temporary suspension of the trading of its shares Biophytis announces the temporary suspension of the trading of its shares by Euronext, due to the non-publication of its annual financial report for the fiscal year ended December 31, 2024. The report will be published following certification of the…
Biophytis announces its participation in the BIO International Convention from June 16 to 19 Biophytis announces its participation to the BIO International Convention, which will take place this year in Boston, USA, from June 16 to 19, 2025. Edouard Bieth, Chief Strategy Officer at Biophytis, will be present and will…
Information on the Annual Financial Statements Biophytis announces that, due to exceptional circumstances related to technical complications in the audit process, the publication of its 2024 annual financial statements has been postponed. The Company requires additional time to complete the audit and certification of its accounts. As a result, Biophytis…
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation Biophytis announced its active participation at the 32nd European Congress on Obesity (ECO 2025), held from May 11 to 14 in Malaga, Spain. During this premier international event, which brings together leading experts, clinicians, researchers, and industry stakeholders…
Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended December 31, 2024. Due to the €2.6 million refinancing operation (announced in the press release dated March 26, 2025), the Company had to focus its…
Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.
Our lead drug candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.
BIOPHYTIS ON THE STOCK MARKET
Biophytis has been listed on the market Euronext Growth Paris since July 13, 2015.
ISIN FR001400OLP5
Ticker: ALBPS
Type of listing: continuous
Total number of shares at 30/06/2025: 23,434,088
1 ADR = 10 shares
Number of voting rights at 30/06/2025: 23,468,567
Eligible for PEA and PEA-PME equity saving plans
Click here for live stock price